Background: The Colombian National Food and Drug Surveillance Institute (INVIMA) is
responsible for monitoring the safety and efficacy of medicines circulating the Colombian market.
Discussion: This article summarizes the three key strategies the institution has implemented to
strengthen the National Pharmacovigilance Program: improving the interaction and working
relationship with regional health authorities, expanding the National Pharmacovigilance Network and
implementing the electronic submission of adverse events.
Conclusion: The number of adverse events reported in Colombia increased from 5,447 in 2013 to 95,658
in 2017, reaching a population-based reporting ratio within international standards (563 in 2016).